MiNK Therapeutics (INKT) News Today $14.62 -0.29 (-1.95%) Closing price 04:00 PM EasternExtended Trading$14.62 +0.01 (+0.03%) As of 05:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INKT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period MiNK Therapeutics, Inc. (NASDAQ:INKT) Short Interest UpdateAugust 17 at 2:37 PM | marketbeat.comMiNK Therapeutics (NASDAQ:INKT) Issues Earnings ResultsAugust 16 at 11:43 PM | marketbeat.comHC Wainwright & Co. Upgrades MiNK Therapeutics (INKT)August 16 at 2:29 AM | msn.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q2 2025 Earnings Call TranscriptAugust 15 at 9:12 AM | insidermonkey.comMiNK Therapeutics Reports Q2 2025 Milestones and FinancialsAugust 15 at 4:16 AM | msn.comMiNK Therapeutics outlines multiple late-stage catalysts and targets Phase II gastric cancer data by end of 2025 while expanding partnershipsAugust 14, 2025 | msn.comMiNK Therapeutics reports Q2 EPS ($1.06) vs (73c) last yearAugust 14, 2025 | msn.comMiNK INKT Q2 2025 Earnings Call TranscriptAugust 14, 2025 | fool.comMiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 ResultsAugust 14, 2025 | globenewswire.comMiNK Therapeutics (INKT) to Release Quarterly Earnings on ThursdayAugust 12, 2025 | americanbankingnews.comMiNK Therapeutics (INKT) Projected to Post Earnings on ThursdayAugust 7, 2025 | marketbeat.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Sees Large Increase in Short InterestAugust 2, 2025 | marketbeat.comMink Therapeutics Inc News (INKT) - Investing.comAugust 1, 2025 | investing.comMiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial ReportJuly 31, 2025 | globenewswire.comLongbow Finance SA Reduces Holdings in MiNK Therapeutics, Inc. (NASDAQ:INKT)July 26, 2025 | marketbeat.comMiNK Therapeutics (NASDAQ:INKT) Upgraded to Strong-Buy at B. RileyJuly 19, 2025 | marketbeat.comMiNK Therapeutics: Moving Out Of The Hunt's Early DaysJuly 16, 2025 | seekingalpha.comWilliam Blair Downgrades MiNK Therapeutics (INKT)July 16, 2025 | msn.comHC Wainwright Reiterates Neutral Rating for MiNK Therapeutics (NASDAQ:INKT)July 15, 2025 | marketbeat.comMiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell TherapyJuly 15, 2025 | globenewswire.comMiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell TherapyJuly 15, 2025 | globenewswire.comMiNK Therapeutics Enters $50M Sales Agreement with B. RileyJuly 15, 2025 | tipranks.comMiNK Therapeutics Shares Drop Sharply Following William Blair DowngradeJuly 14, 2025 | msn.comMiNK Therapeutics stock falls after William Blair downgradeJuly 14, 2025 | finance.yahoo.comPromising Small Cap Stocks To Watch Now - July 13thJuly 13, 2025 | marketbeat.comPharmaceutical Stocks Worth Watching - July 13thJuly 13, 2025 | marketbeat.comMiNK Therapeutics Announces Publication of Complete Remission Following ...July 13, 2025 | seekingalpha.comMiNK Therapeutics: AgenT-797 Solidifies Itself As iNKT Cell Therapy With Latest CR DataJuly 13, 2025 | seekingalpha.comPromising Medical Stocks To Add to Your Watchlist - July 13thJuly 13, 2025 | marketbeat.comWhy Is MiNK Therapeutics Stock (INKT) Up 190% Today?July 12, 2025 | msn.comMiNK Therapeutics stock soars after cancer remission breakthroughJuly 11, 2025 | investing.comMiNK Therapeutics Shares Surge After Remission Case Published in Scientific JournalJuly 11, 2025 | marketwatch.comMiNK Therapeutics Stock Soars On Patient Receiving Full Remission In Testicular Cancer With Investigational Cell TherapyJuly 11, 2025 | msn.comMiNK Therapeutics Shares Skyrocket After Landmark Cancer Remission ResultJuly 11, 2025 | msn.comBest Small Cap Stocks To Watch Today - July 11thJuly 11, 2025 | marketbeat.comPharmaceutical Stocks To Keep An Eye On - July 11thJuly 11, 2025 | marketbeat.comBest Medical Stocks To Keep An Eye On - July 11thJuly 11, 2025 | marketbeat.comWhy Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?July 11, 2025 | benzinga.comMiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular CancerJuly 11, 2025 | finance.yahoo.comMiNK Therapeutics Announces Virtual Annual Shareholders MeetingJune 10, 2025 | globenewswire.comMiNK Therapeutics Receives NIAID Grant to Advance Allo-iNKT Cell Therapy for Graft-Versus-Host Disease TreatmentJune 4, 2025 | nasdaq.comMiNK Therapeutics ontvangt NIH-subsidie voor GvHD-therapieJune 2, 2025 | nl.investing.comMiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant PatientsJune 2, 2025 | globenewswire.comMiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2025 Earnings Call TranscriptMay 17, 2025 | msn.comQ1 2025 Mink Therapeutics Inc Earnings CallMay 16, 2025 | finance.yahoo.comMiNK Therapeutics Inc (INKT) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...May 16, 2025 | finance.yahoo.comMiNK Therapeutics outlines near-term partnering proposals and reduced cash burn as company advances iNKT programsMay 15, 2025 | msn.comMiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comMiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic ProgressMay 15, 2025 | globenewswire.comA Look at MiNK Therapeutics's Upcoming Earnings ReportMay 14, 2025 | benzinga.com Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address INKT Media Mentions By Week INKT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INKT News Sentiment▼0.200.66▲Average Medical News Sentiment INKT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INKT Articles This Week▼132▲INKT Articles Average Week Get MiNK Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INKT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies enGene News Today GENFIT News Today Eupraxia Pharmaceuticals News Today C4 Therapeutics News Today Innate Pharma News Today Puma Biotechnology News Today China SXT Pharmaceuticals News Today Instil Bio News Today Journey Medical News Today Cybin News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INKT) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredTrump’s SHOCKING Plan to Create MASSIVE Wealth for AmericansJames Altucher says Donald Trump just made a move so surprising, it could go down as the most lucrative presid...Paradigm Press | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access